HIV/AIDS treatment remains successful, but TB rise a concern

(London) – A decade after the introduction of highly active antiretroviral therapy (HAART) in Europe and North America, the risk of AIDS and death remains low for those starting treatment, according to a study published in The Lancet.

However, there has been a rise in tuberculosis among patients starting HAART in recent years.

Dr. Robert S. Hogg, a director of the B.C. Centre for Excellence in HIV/AIDS, contributed to discussions on statistical analyses and to writing the paper as a member of the study’s Antiretroviral Therapy (ART) Cohort Collaboration.

HAART, which was introduced a decade ago for the treatment of HIV infection, has resulted in 80% to 90% reductions in rates of AIDS and death compared with patients who are not treated. To investigate whether the prognosis for patients taking this therapy has changed over time, Margaret May and colleagues analysed data from over 22 200 HIV infected patients in Europe and North America. The patients had started HAART for the first time in 1995-96, 1997, 1998, 1999, 2000, 2001, and 2002-03. Although patients’ control of the HIV virus improved over the years, their risk of death in the first year after starting treatment has remained approximately the same. There was evidence that the risk of AIDS has increased since 1998. The researchers found that this was largely attributable to an increase in tuberculosis.

Co-author Margaret May comments:”The discrepancy between the clear improvement we recorded for virological response and the apparently worsening rates of clinical progression might be related to the change in demographic characteristics of the study participants, with an increasing number of patients from areas with a high incidence of tuberculosis.”

The researchers also found that many patients had started HAART at a more advanced stage of HIV disease than is recommended by treatment guidelines. Early diagnosis and treatment of those with HIV-infection is needed to prevent progression to AIDS. An expansion of voluntary and cost-effective screening in health-care settings is likely to result in improved patient care and prognosis.

Share the Post:
Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below

Laboratory Order Forms

Start typing and press enter to search